

AMENDMENT AND RESPONSE TO OFFICE ACTION


In the Claims

1. (previously presented) A drug delivery composition comprising a biodegradable, aliphatic poly(ester-anhydride) copolymer comprising random ester bonds along the polymer chain and a biologically active agent.

2. (original) The composition of claim 1, wherein the biologically active agent is selected from the group consisting of small drug molecules, peptides and proteins, DNA and DNA complexes with cationic molecules.

3. (original) The composition of claim 1, wherein the composition is in a form suitable for administration by injection.

4. (currently amended) The composition of claim 1, wherein the polymer is a poly(ester-anhydride) with the formula:



where R is a linear or branched aliphatic or aromatic moiety when $x+y=1$ and x is not 0, or R is an unsaturated fatty acid with at least one *cis*-double bond, or an ester of ricinoleic acid, R' is a ricinoleic acid residue, R'' is an aliphatic moiety, and n is an integer from 1 to 200.

AMENDMENT AND RESPONSE TO OFFICE ACTION

5. (original) The composition of claim 4, wherein R is a natural or synthetic fatty acid selected from the group consisting of: oleic acid, ricinoleic acid, and linolenic acid.

6. (currently amended) The composition of claim 1, wherein the poly(ester-anhydride) comprises one or more monomers derived from a hydroxy acid or dicarboxylic acid is selected from the group consisting of C₄ to C₂₂ linear alkane dicarboxylic acids, dimer erucic acid, dimer oleic acid, ~~and non-linear fatty acid-ester derivatives of ricinoleic acid, fumarate or succinate, oligomers or polymers of hydroxyl acids,~~ and mixtures thereof.

7. (currently amended) The composition of claim 6, wherein the ~~dicarboxylic~~ hydroxy acid is ~~a derivative of oligomers or polymers~~ an oligomer or polymer of hydroxy acids.

8. (original) The composition of claim 1, wherein the polymer is prepared from purified ricinoleic acid, wherein ricinoleic acid comprises at least 90% by weight of the polymer.

9. (original) The composition of claim 1, wherein the biologically active agent is encapsulated in microparticles or nanoparticles.

10. (original) The composition of claim 2, wherein the biologically active agent is selected from the group consisting of the group consisting of antibacterial, anti-inflammatory and anticancer agents, antidepressants, analgesics and local anesthetics.

Claims 11-14. Canceled

15. (currently amended) The composition of claim 4, wherein the poly(ester anhydride) copolymer comprises monomers derived from a dicarboxylic acid selected from the group consisting of dodecanedioic acid and sebacic acid and comonomers derived from ricinoleic acid,

AMENDMENT AND RESPONSE TO OFFICE ACTION

a ~~derivative thereof~~, non-linear fatty acid-esters derivatives of ricinoleic acid, or an oligoester thereof.

16. (previously presented) The composition of claim 15, wherein the polymer is terminated with a fatty acid selected from the group consisting of oleic acid, linoleic acid, and linolenic acid.

17. (previously presented) A drug delivery composition comprising a biodegradable poly(ester-anhydride) copolymer comprising random ester bonds along the polymer chain and a biologically active agent, wherein the copolymer comprises monomers derived from ricinoleic acid and sebacic acid.

18. (previously presented) The composition of claim 17, the polymer is a copolymer of sebacic acid and ricinoleic acid.

19. (previously presented) The drug delivery composition of claim 18, wherein the ratio of monomers derived from ricinoleic acid to monomers derived from sebacic acid is 8:2 or 7:3.

20. (previously presented) The composition of claim 17, wherein the biologically active agent is selected from the group consisting of small drug molecules, peptides and proteins, DNA and DNA complexes with cationic molecules.

21. (previously presented) The composition of claim 17, wherein the composition is in a form suitable for administration by injection.

22. (previously presented) The composition of claim 17, wherein the polymer is prepared from purified ricinoleic acid, wherein ricinoleic acid comprises at least 90% by weight of the polymer.

AMENDMENT AND RESPONSE TO OFFICE ACTION

23. (previously presented) The composition of claim 17, wherein the biologically active agent is encapsulated in microparticles or nanoparticles.

24. (previously presented) The composition of claim 20, wherein the biologically active agent is selected from the group consisting of the group consisting of antibacterial, anti-inflammatory and anticancer agents, antidepressants, analgesics and local anesthetics.

25. (new) The composition of claim 7, wherein the hydroxy acid is selected from the group consisting of lactic acid, glycolic acid, hydroxybutyric acid, hydroxycaproic acid, hydroxybenzoic acid, mucic acid, tartaric acid, pentahydroxycyclohexane carboxylic acid and combinations thereof.